Affiliation:
1. National Institute of Pneumophthisiology “Marius Nasta” , Bucharest
2. “Carol Davila” University of Medicine and Pharmacy , Bucharest
Abstract
Abstract
Sarcoidosis is a systemic condition characterized by the formation of non-caseating granulomas in any organ or tissue, with a predominant impact on the lungs and intrathoracic lymph nodes(1). The heterogeneity of the disease is reflected in the broad possibilities of the clinical and paraclinical evolution, which can range from the incidental identification of the disease in an asymptomatic patient to the progressive chronic involvement of the affected organs. Commonly, sarcoidosis initially manifests through nonspecific respiratory symptoms, characterized by dry cough, dyspnea, chest pain, and fatigue(2,3). Generally, it is considered that this condition occurs in individuals with a susceptible genetic background, exposed to certain environmental factors or antigens that remain unknown, despite numerous existing hypotheses(4).
Cardiac involvement in sarcoidosis has a significant negative impact on prognosis. Although this location of the disease is predominantly silent, 5% of cases present with dilated or restrictive cardiomyopathy, progressive heart failure, high-grade atrioventricular blocks, and ventricular arrhythmias(5).
The authors present the case of a young patient who, although at the onset of the disease, exhibited a typical clinical and imaging profile of sarcoidosis, myocardial involvement - a rare localization of this pathology - was detected during the course of the condition. Patients with sarcoidosis may have normal spirometry, may present with a restrictive syndrome (similar to diffuse interstitial lung diseases), or an obstructive syndrome, secondary to the involvement of small bronchi and bronchial distortions caused by the disease, often with an unfavorable prognosis.
Reference15 articles.
1. Soto-Gomez N, P. J. (2016, Mai 15). Diagnosis and Management of Sarcoidosis. Am Fam Physician, 93(10), 840-8.
2. Drent M, C. E. (2021). Challenges of sarcoidosis and its management. N Engl J Med, 385(11), 1018–1032.
3. Miedema J, N. H. (2021). Drug-induced sarcoidosis-like reactions. Curr Opin Pulm Med, 27(5), 439–447.
4. Claudio Tana, M. D. (2022, Dec). Comorbidities of sarcoidosis. Ann Med, 54(1), 1014-1035.
5. Kristyna Kysperska, P. K. (2021). Cardiac sarcoidosis: from diagnosis to treatment. Biomedical Papers, 165(4), 347-359.